I’ve never bred any babies of my own (well, at least to the best of my knowledge). But have helped several friends in what must be one of the most taxing tasks ever known to mankind: that of finding appropriate names for babies. While some of us want baby names to be unique, others are content with simply naming them after their favourite gods, goddesses, sport-stars, rock-stars, cine-stars…you name it! And yet others don’t give a damn…name and be done […]
As we had reported earlier, the Division Bench of the Madras High Court had ordered the State Government and the Central Government to co-operate in relocating the IPAB to a new office with adequate space. The State Government came back with a proposal to relocate the IPAB at the TIDEL Park Building which had the required space. The proposed rent was pegged at about Rs. 15 lakhs per month. Apparently the Central Government found this to be too expensive and
An update on the PILs against the IPAB and the Copyright Board Read More »
Shah Rukh Khan’s latest film venture, RA.One, an expensive affair to begin with, just got costlier by Rs. One crore, for a potential intellectual property rights violation. This isn’t the first time the release of an expected Bollywood blockbuster has been hindered by the prospect of having violated provisions of the Indian Copyright Act. Interestingly in this case, the court did not not stay the release of the film, but rather asked SRK’s company, Red Chillies Entertainment to deposit Rs.
Shah Rukh Khan’s RA.One in Copyright Dispute Read More »
FICCI has launched an Online Certificate Course on Intellectual Property, for which registrations are scheduled to begin next month. FICCI sends us the following information on the course, and related registration details. Please don’t forget to mention you came via SpicyIP! — Federation of Indian Chambers of Commerce and Industry (FICCI) has started an Online Certificate Course on Intellectual Property (IP). The objective of the Course is to increase awareness about IP in the Society for the benefit of the
FICCI launches Online Certificate Course in IP Read More »
School ties are easy enough to get rid of. Mine was navy blue, with sky blue stripes on it. Not very pretty, but I have still kept it, grudgingly, to remind me of those horror-some years. But college ties are a completely different story. As I was to discover in the three years after school. It’s been a while since, but college is still not out of mind. (image from here) But enough about me and my collection of ties.
Of ties, school ties and alumni Read More »
The genesis of SpicyIP in 2005 had strong roots in the fervent desire to weed out corruption at Indian IP offices, by interalia, fostering greater levels of transparency. While we’ve witnessed some modest success along the way, it really falls several notches short of what we initially set out to do. All of us have day jobs/preoccupations that cast serious limitations on the time that we have at our disposal, but that is no excuse. The road to transparency has
Reflecting on the Transparency Crusade Read More »
While Novartis was the first land mark case on Section 3(d), it was the Roche-Cipla tussle over Indian Patent No. 196774, which laid down the first judicial precedent for the grant of interim injunctions in the case of infringement of pharmaceutical patents. This infringement suit was filed in January, 2008 and Justice Bhat subsequently delivered orders on the interim injunction application within 2 months. The matter then went to trial, which is now complete and should hopefully be argued before
The regular readers of Spicy IP may already be familiar with Managing IP, an organization providing global resources for IP news and analysis, whose IP webinars have often been announced and reported in the past in this blog (here, for example). One of the resource units in the Managing IP website concentrates exclusively on relevant and contemporary India-specific IP issues, titled India IP Focus. The latest edition of India IP focus, for example, brings for the readers a wonderful repository
Managing IP brings India IP Focus 8th Edition Read More »
Indian generics Aurobindo Pharma Limited and MedChem, yesterday joined the Medicines Patent Pool (MPP) for the manufacture of several antiretroviral medicines. While Aurobindo is a well established generic unit which already produces antiretrovirals, MedChem is apparently a new comer into the HIV field. [The MPP is a patent pool which seeks to facilitate the innovation and production of ARVs in developing countries — we have written on it before here] This will allow Aurobindo to have access and produce the products that Gilead
SpicyIP Tidbit: Indian generic companies now step into MPP Read More »
There has been considerable world-wide interest over NATCO’s compulsory licensing application for Indian patent number 215758 i.e. Bayer’s patent for Sorafenib, which is marketed under the brand Nexavar. It’s the first such application post 2005 and is widely seen as the test case. Considering that the patent belongs to an American company it is likely that this issue will reverberate at the WTO. We had earlier blogged on this CL, over here and here. NATCO’s CL application is available over
The absence of evidence in NATCO’s CL application for Nexavar Read More »
